NASDAQ:AGLE Aeglea BioTherapeutics (AGLE) Stock Forecast, Price & News $11.86 +0.19 (+1.63%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$11.57▼$12.7250-Day Range$10.86▼$16.9252-Week Range$2.66▼$39.00Volume52,216 shsAverage Volume107,846 shsMarket Capitalization$48.03 millionP/E RatioN/ADividend YieldN/APrice Target$24.38 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aeglea BioTherapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside105.5% Upside$24.38 Price TargetShort InterestHealthy1.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.95) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector486th out of 968 stocksPharmaceutical Preparations Industry210th out of 445 stocks 3.2 Analyst's Opinion Consensus RatingAeglea BioTherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.38, Aeglea BioTherapeutics has a forecasted upside of 105.5% from its current price of $11.86.Amount of Analyst CoverageAeglea BioTherapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.52% of the float of Aeglea BioTherapeutics has been sold short.Short Interest Ratio / Days to CoverAeglea BioTherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aeglea BioTherapeutics has recently decreased by 96.08%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAeglea BioTherapeutics does not currently pay a dividend.Dividend GrowthAeglea BioTherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AGLE. Previous Next 1.8 News and Social Media Coverage News SentimentAeglea BioTherapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aeglea BioTherapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for AGLE on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeglea BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Aeglea BioTherapeutics is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aeglea BioTherapeutics are expected to grow in the coming year, from ($3.95) to ($1.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeglea BioTherapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeglea BioTherapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeglea BioTherapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aeglea BioTherapeutics (NASDAQ:AGLE) StockAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Read More AGLE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGLE Stock News HeadlinesSeptember 18, 2023 | americanbankingnews.comAeglea BioTherapeutics (NASDAQ:AGLE) Rating Increased to Hold at StockNews.comSeptember 16, 2023 | americanbankingnews.comAeglea BioTherapeutics (NASDAQ:AGLE) Upgraded to "Hold" at StockNews.comSeptember 22, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 14, 2023 | finance.yahoo.comAeglea BioTherapeutics to Participate in Upcoming September ConferenceSeptember 14, 2023 | americanbankingnews.comAeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Sees Significant Decrease in Short InterestSeptember 14, 2023 | markets.businessinsider.comAeglea Biotherapeutics (AGLE) Gets a Buy from Stifel NicolausSeptember 13, 2023 | americanbankingnews.comAeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Receives Average Rating of "Hold" from BrokeragesSeptember 8, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Announces Reverse Stock SplitSeptember 22, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 7, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Reverse Stock SplitSeptember 5, 2023 | seekingalpha.comAeglea BioTherapeutics appoints Burrows as CFO, King-Jones as CLOSeptember 5, 2023 | markets.businessinsider.comAeglea BioTherapeutics Appoints Scott Burrows As Chief Financial OfficerSeptember 5, 2023 | finance.yahoo.comAeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesAugust 16, 2023 | msn.comWells Fargo Maintains Aeglea BioTherapeutics (AGLE) Equal-Weight RecommendationAugust 11, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | fool.comAeglea BioTherapeutics (NASDAQ: AGLE)August 3, 2023 | msn.comAeglea BioTherapeutics (AGLE) Price Target Decreased by 54.54% to 1.45July 27, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica PharmaJuly 25, 2023 | seekingalpha.comAeglea initiated with Buy at Stifel citing potential in IBD spaceJuly 25, 2023 | msn.comStifel Initiates Coverage of Aeglea BioTherapeutics (AGLE) with Buy RecommendationJuly 25, 2023 | markets.businessinsider.comAeglea Biotherapeutics (AGLE) Initiated with a Buy at Stifel NicolausJune 26, 2023 | bizjournals.comFunding wrap: Former Dell Med dean raises $30MJune 23, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Grant of Inducement AwardsJune 23, 2023 | bizjournals.comM&A Wrap: Aeglea grabs another biotech co., $210M; Wealth manager acquiredJune 22, 2023 | proactiveinvestors.comAeglea BioTherapeutics stock skyrockets as it boosts inflammatory bowel disease portfolio with Spyre Therapeutics acquisitionJune 22, 2023 | investorplace.comWhy Is Aeglea BioTherapeutics (AGLE) Stock Up 392% Today?See More Headlines Receive AGLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGLE Company Calendar Last Earnings8/11/2023Today9/22/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGLE CUSIPN/A CIK1636282 Webwww.aegleabio.com Phone(512) 942-2935Fax512-872-5121Employees14Year FoundedN/APrice Target and Rating Average Stock Price Forecast$24.38 High Stock Price Forecast$37.50 Low Stock Price Forecast$12.50 Forecasted Upside/Downside+98.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($71.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,820,000.00 Net Margins-22,195.36% Pretax Margin-22,209.53% Return on Equity-132.05% Return on Assets-186.96% Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio1.03 Sales & Book Value Annual Sales$2.33 million Price / Sales21.33 Cash FlowN/A Price / Cash FlowN/A Book Value$20.45 per share Price / Book0.60Miscellaneous Outstanding Shares4,050,000Free Float3,918,000Market Cap$49.69 million OptionableOptionable Beta2.53 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Jonathan D. Alspaugh M.B.A. (Age 40)Pres, CFO & Principal Accounting Officer Comp: $568.55kMr. James Paul Kastenmayer J.D. (Age 51)Ph.D., Consultant Comp: $611.84kDr. Cameron Turtle DPHIL (Age 33)Ph.D., Chief Operating Officer Joey PerroneVP of Fin. & Investor RelationsDr. Kelly Boothe Ph.D.Sr. Director of Corp. Communications & Investor RelationsMs. Cortney Caudill M.B.A.Chief Product OfficerMore ExecutivesKey CompetitorsvTv TherapeuticsNASDAQ:VTVTAssembly BiosciencesNASDAQ:ASMBSocietal CDMONASDAQ:SCTLDianthus TherapeuticsNASDAQ:DNTHCelularityNASDAQ:CELUView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCBought 4,900,000 shares on 8/21/2023Ownership: 7.494%Commodore Capital LPBought 2,908,100 shares on 8/15/2023Ownership: 4.447%Goldman Sachs Group Inc.Bought 558,650 shares on 8/15/2023Ownership: 0.854%Driehaus Capital Management LLCBought 4,643,357 shares on 8/14/2023Ownership: 7.101%BlackRock Inc.Sold 119,751 shares on 8/11/2023Ownership: 0.809%View All Institutional Transactions AGLE Stock - Frequently Asked Questions Should I buy or sell Aeglea BioTherapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGLE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGLE, but not buy additional shares or sell existing shares. View AGLE analyst ratings or view top-rated stocks. What is Aeglea BioTherapeutics' stock price forecast for 2023? 6 Wall Street analysts have issued 1 year price targets for Aeglea BioTherapeutics' stock. Their AGLE share price forecasts range from $12.50 to $37.50. On average, they anticipate the company's share price to reach $24.38 in the next twelve months. This suggests a possible upside of 98.7% from the stock's current price. View analysts price targets for AGLE or view top-rated stocks among Wall Street analysts. How have AGLE shares performed in 2023? Aeglea BioTherapeutics' stock was trading at $11.2475 on January 1st, 2023. Since then, AGLE shares have increased by 9.1% and is now trading at $12.27. View the best growth stocks for 2023 here. Are investors shorting Aeglea BioTherapeutics? Aeglea BioTherapeutics saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 61,600 shares, a decrease of 96.1% from the August 15th total of 1,570,000 shares. Based on an average daily volume of 256,400 shares, the short-interest ratio is presently 0.2 days. Currently, 1.5% of the company's shares are sold short. View Aeglea BioTherapeutics' Short Interest. When is Aeglea BioTherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our AGLE earnings forecast. How were Aeglea BioTherapeutics' earnings last quarter? Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($41.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.50) by $37.00. The biotechnology company had revenue of $0.69 million for the quarter. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 132.05% and a negative net margin of 22,195.36%. When did Aeglea BioTherapeutics' stock split? Aeglea BioTherapeutics's stock reverse split before market open on Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO? 3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Aeglea BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA). When did Aeglea BioTherapeutics IPO? (AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager. What is Aeglea BioTherapeutics' stock symbol? Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE." Who are Aeglea BioTherapeutics' major shareholders? Aeglea BioTherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include VR Adviser LLC (9.70%), Affinity Asset Advisors LLC (7.49%), Driehaus Capital Management LLC (7.10%), Commodore Capital LP (4.45%), Goldman Sachs Group Inc. (0.85%) and BlackRock Inc. (0.81%). Insiders that own company stock include Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza. View institutional ownership trends. How do I buy shares of Aeglea BioTherapeutics? Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aeglea BioTherapeutics' stock price today? One share of AGLE stock can currently be purchased for approximately $12.27. How much money does Aeglea BioTherapeutics make? Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $49.69 million and generates $2.33 million in revenue each year. The biotechnology company earns $-83,820,000.00 in net income (profit) each year or ($71.00) on an earnings per share basis. How can I contact Aeglea BioTherapeutics? Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121. This page (NASDAQ:AGLE) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeglea BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.